Form 4: Emergent BioSolutions Inc. (EBS), Richard Ronald, transaction 08/07/2020
Summary
Director Richard Ronald is the reporting person on this Emergent BioSolutions Inc. [EBS] Form 4, which reports a sale of 6,297 shares of common stock on August 7, 2020, at $131. The form lists 8,276 shares owned directly after the sale. The explanation of responses states that, due to a computational error in the Form 4 filed on February 25, 2020, later filings showed the incorrect amount of securities beneficially owned, and that the amount is corrected in this form. It is signed /s/ S. Scott Lieberman, Attorney-in-fact, on August 11, 2020.
Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used
Cite this document
“Form 4: Emergent BioSolutions Inc. (EBS), Richard Ronald, transaction 08/07/2020.”
Original at www.sec.gov. Archived at Pandemic Darlings, https://pandemicdarlings.com/source-documents/sec-ebs-4-filed2020-08-11-0001367644-20-000130-20c5441087/
, SHA-256 d99ed887676641995b6fa70ed1f2938014aad398dbb8af20776d01cd54f13bee.Full text
SEC Form 4 FORM 4 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 | OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB APPROVAL | OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB Number: | 3235-0287 | Estimated average burden | hours per response: | 0.5 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). 1. Name and Address of Reporting Person * Richard Ronald (Last) (First) (Middle) 400 PROFESSIONAL DR, SUITE 400 (Street) GAITHERSBURG MD 20879 (City) (State) (Zip) | Richard Ronald | (Last) | (First) | (Middle) | 400 PROFESSIONAL DR, SUITE 400 | GAITHERSBURG | MD | 20879 | (City) | (State) | (Zip) | 2. Issuer Name and Ticker or Trading Symbol Emergent BioSolutions Inc. [ EBS ] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title below) Other (specify below) | X | Director | 10% Owner | Officer (give title below) | Other (specify below) 3. Date of Earliest Transaction (Month/Day/Year) 08/07/2020 4. If Amendment, Date of Original Filed (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | X | Form filed by One Reporting Person | Form filed by More than One Reporting Person Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code | V | Amount | (A) or (D) | Price Common Stock (1) | 08/07/2020 | S | 6,297 | D | $ 131 | 8,276 (2) | D Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares Explanation of Responses: 1. Consists of restricted stock units granted under the Company's Stock Incentive Plan, as amended and restated. 2. Due to a computational error in the Form 4 filed on February 25, 2020, Mr. Richard's subsequently filed From 4s showed the incorrect amount of securities beneficially owned. The amount of securities beneficially owned has been corrected herein. Remarks: /s/ S. Scott Lieberman, Attorney-in-fact | 08/11/2020 ** Signature of Reporting Person | Date Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
File and source
- File
- SEC_EBS_4_filed2020-08-11_0001367644-20-000130.xml
- Size
- 15,326 bytes
- SHA-256
- d99ed887676641995b6fa70ed1f2938014aad398dbb8af20776d01cd54f13bee
- Original
- www.sec.gov